Modulator therapy does not appear to affect the magnitude of lung function impairment or recovery pattern during pulmonary ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

Treatment with elexacaftor-tezacaftor-ivacaftor is associated with reduced levels of systemic inflammatory markers, which ...

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay cystic fibrosis treatment saw revenue growth while new drugs’ performances ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the third quarter.

The Russell Midcap® Growth Index (up 2.78%) underperformed the Russell Midcap® Value Index (up 6.16%), losing some momentum after a notably strong second quarter.

Patients go without needed treatment as shutdown disrupts a telehealth Each week Hot off the Wire looks at a variety of stories in business, science, health and more. This week's headlines include: ...